Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Blood (2023) 142 (11): 961–972.

https://doi.org/10.1182/blood.2023020013

Published: 2023

Includes: Supplemental data

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Blood (2022) 140 (Supplement 1): 834–836.

https://doi.org/10.1182/blood-2022-163245

Published: 2022

Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Blood (2022) 139 (9): 1318–1329.

https://doi.org/10.1182/blood.2021013208

Published: 2022

Includes: Supplemental data

Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek

Blood (2021) 138 (19): 1805–1816.

https://doi.org/10.1182/blood.2020010484

Published: 2021

Includes: Supplemental data

Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Blood (2020) 136 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2020-134827

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Blood (2019) 134 (Supplement_1): 36.

https://doi.org/10.1182/blood-2019-125825

Published: 2019

Journal Articles

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Anna Maria Fink, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Michael Kneba, MD PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Kirsten Fischer, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 3040.

https://doi.org/10.1182/blood-2019-125063

Published: 2019

Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen

Blood (2019) 133 (5): 494–497.

https://doi.org/10.1182/blood-2018-03-839688

Published: 2019

Includes: Supplemental data

Journal Articles

Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)

Paula Cramer, Julia von Tresckow, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Eugen Tausch, MD, Moritz Fürstenau, MD, Petra Langerbeins, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, MD PhD, Michael Hallek

Blood (2018) 132 (Supplement 1): 694.

https://doi.org/10.1182/blood-2018-99-113155

Published: 2018

Journal Articles

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Blood (2018) 132 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2018-99-113257

Published: 2018

Journal Articles

Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

Moritz Fürstenau, MD, Jasmin Bahlo, PhD, Anna-Maria Fink, MD, Elisabeth Lange, Peter Dreger, MD, Martin Dreyling, MD PhD, Georg Hess, Matthias Ritgen, MD, Michael Kneba, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Sebastian Böttcher, Michael Hallek, Barbara Eichhorst

Blood (2018) 132 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2018-99-113280

Published: 2018

Journal Articles

CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial

Monika Szczepanowski, PhD, Johanna Richter, Britta Kehden, Matthias Ritgen, MD, Heiko Trautmann, PhD, Henrik Knecht, PhD, Mustafa Kondakci, MD, Christoph Faul, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1409.

https://doi.org/10.1182/blood-2018-99-114673

Published: 2018

Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 396.

https://doi.org/10.1182/blood-2018-99-115930

Published: 2018

Journal Articles

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Blood (2018) 132 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2018-99-115167

Published: 2018

Journal Articles

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Michaela Kotrova, MD PhD, Monika Szczepanowski, PhD, Henrik Knecht, PhD, Christoph Faul, MD, Mustafa Kondakci, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Nikos Darzentas, PhD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2018-99-112844

Published: 2018

Journal Articles

IG- MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas

Blood (2018) 132 (21): 2280–2285.

https://doi.org/10.1182/blood-2018-03-842088

Published: 2018

Includes: Supplemental data

Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

Blood (2018) 131 (9): 955–962.

https://doi.org/10.1182/blood-2017-06-792333

Published: 2018

Includes: Supplemental data

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

NARROW

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

IG- MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only